Skip to main content

Table 3 Results of sensitivity analysis

From: Meta-analysis: preoperative transcatheter arterial chemoembolization does not improve prognosis of patients with resectable hepatocellular carcinoma

Outcome No. of studies No.of patients Results OR (95% CI) P value HG p value
TACE (+) TACE (−) TACE (+) TACE (−)
RCTs         
5-years disease-free survival 4[1416, 24] 167 172 29.3% 31.9% 0.85 (0.53, 1.39) 0.52 0.16
5-years overall survival 4[1416, 24] 167 172 36.5% 38.3% 0.89 (0.56, 1.41) 0.61 0.11
Total recurrence 3[14, 16, 24] 116 124 74.1% 74.2% 1.03 (0.36, 2.90) 0.96 0.07
Intrahepatic recurrence 3[14, 16, 24] 116 124 50.0% 46.7% 1.32 (0.47, 3.70) 0.59 0.02
Extrahepatic recurrence 3[14, 16, 24] 116 124 28.4% 22.5% 1.37 (0.42, 4.43) 0.60 0.04
Overall morbidity 3[14, 16, 24] 113 127 20.3% 21.2% 0.97 (0.52, 1.82) 0.93 0.14
Mortality 4[1416, 24] 163 174 3.1% 4.0% 0.70 (0.22, 2.30) 0.56 0.95
NRCTs         
5-years disease-free survival 14[10, 11, 13, 28, 3140] 1108 1395 32.4% 29.8% 1.28 (0.98, 1.67) 0.07 0.04
5-years overall survival 12[11, 12, 28, 29, 31, 3440] 871 1291 40.9% 46.1% 0.86 (0.55, 1.32) 0.48 <0.01
Total recurrence 8[10, 30, 32, 35, 36, 3840] 559 795 58.1% 55.8% 0.98 (0.77, 1.25) 0.86 0.11
Intrahepatic recurrence 9[1012, 29, 30, 32, 35, 36, 39] 546 675 51.2% 56.5% 0.79 (0.62, 1.01) 0.06 0.84
Extrahepatic recurrence 6[10, 30, 32, 35, 36, 39] 403 467 8.4% 7.0% 1.22 (0.73, 2.06) 0.44 0.74
Overall morbidity 8[1012, 29, 30, 35, 36, 40] 470 676 31.0% 27.9% 1.03 (0.79, 1.36) 0.81 0.50
Mortality 12[1012, 2830, 3336, 38, 40] 937 1151 4.3% 2.9% 1.39 (0.85, 2.28) 0.19 0.74
Studies with complete matched clinicopathological parameters         
5-years disease-free survival 6[15, 16, 28, 32, 35, 39] 421 404 26.8% 22.0% 1.13 (0.62, 2.05) 0.69 0.02
5-years overall survival 7[12, 15, 16, 28, 32, 35, 39] 452 511 44.6% 35.2% 1.15 (0.76, 1.74) 0.50 0.08
Total recurrence 5[16, 30, 32, 35, 39] 297 349 73.7% 76.5% 0.91 (0.62, 1.33) 0.64 0.15
Intrahepatic recurrence 6[12, 16, 30, 32, 35, 39] 328 456 56.4% 60.1% 0.81 (0.59, 1.11) 0.20 0.69
Extrahepatic recurrence 5[16, 30, 32, 35, 39] 297 349 13.1% 9.4% 1.40 (0.83, 2.38) 0.21 0.80
Overall morbidity 4[12, 16, 30, 35] 191 344 36.1% 28.2% 1.36 (0.91, 2.01) 0.13 0.48
Mortality 6[12, 15, 16, 28, 30, 35] 339 423 4.4% 3.7% 1.16 (0.52, 2.57) 0.71 0.50
  1. HG heterogeneity.